U.S. stock futures slip lower; Cook’s firing increases Fed independence worries
Investing.com - Citizens JMP has reiterated its Market Perform rating on Apyx Medical (TASE:BLWV) Corp. (NASDAQ:APYX), a $77 million market cap medical device company, following its second-quarter 2025 financial results. The stock has shown remarkable strength with a 64% gain over the past year.
The medical device company reported quarterly sales of $11.4 million, representing a 6% year-over-year decline and falling slightly below Street expectations of $11.7 million. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.7x, though it is not yet profitable.
Despite the modest quarterly miss, Apyx Medical raised its full-year revenue guidance by approximately 6%, or $3 million in absolute terms, to $51.0 million at the midpoint.
The company attributed the guidance increase to management’s expectations for the full commercial launch of its AYON system, which is anticipated to ramp up in the second half of the year.
Citizens JMP noted that the second-quarter shortfall was partially due to a strategic decision to have sales representatives focus on pre-sales of the AYON system, which exceeded company expectations, to support the upcoming product launch.
In other recent news, Apyx Medical Corporation has made significant strides in its global operations. The company announced the appointment of two new sales executives to bolster its leadership team as part of its global expansion strategy. John Featherstone has been named Vice President of North American Sales, bringing extensive experience from his previous roles at Cytrellis Biosystems, Cutera (OTC:CUTRQ), Inc., and Cynosure. Additionally, Apyx Medical has launched its Renuvion technology in China, following clearance from the National Medical Products Administration of China. This launch is facilitated through a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. These developments mark Apyx Medical’s continued efforts to expand its market presence and product availability internationally.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.